Inactive Instrument

NanoVibronix Inc Stock OTC Bulletin Board

Equities

NAOV

US63008J1088

Medical Equipment, Supplies & Distribution

Sales 2022 752K Sales 2023 2.28M Capitalization 2.35M
Net income 2022 -5M Net income 2023 -3M EV / Sales 2022 7.49 x
Net cash position 2022 2.63M Net cash position 2023 3.28M EV / Sales 2023 -0.41 x
P/E ratio 2022
-1.31 x
P/E ratio 2023
-0.54 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 99.58%
More Fundamentals * Assessed data
Dynamic Chart
NanoVibronix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
NanoVibronix, Inc. Enters into Letter of Intent with APOGEPHA Arzneimittel GmbH to Explore European Distribution Opportunity CI
NanoVibronix, Inc. Signs Research Agreement for Clinical Study of UroShield with University of Michigan CI
NanoVibronix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Investors Eye Fed Moves as US Futures Trend Lower in Friday's Premarket MT
NanoVibronix, Inc. Gains Approval for Inclusion of UroShield Products in NHS Prescription Services' Drug Tariff CI
NanoVibronix Files Registration Statement on Behalf of Selling Shareholders MT
NanoVibronix to Raise $5 Million Through Securities Placement MT
Top Midday Gainers MT
NanoVibronix, Inc. announced that it expects to receive $5 million in funding CI
NanoVibronix Says It's Working to Understand Implications of CMS Decision Related to PainShield Device MT
NanoVibronix, Inc. Applies for Inclusion of Uroshield Products in Nhs Prescription Services' Drug Tariff CI
NanoVibronix Extends Distribution Agreement With Ultra Pain Products for Ultrasound Therapy Devices; Shares Rise MT
NanoVibronix Extends Distribution Agreement with Its Largest Distributor for PainShield and PainShield Plus CI
NanoVibronix, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
More news
Managers TitleAgeSince
Founder 69 03-08-31
Chief Executive Officer 67 16-10-12
Director of Finance/CFO 67 15-02-02
Members of the board TitleAgeSince
Director/Board Member 72 15-04-26
Chairman 74 16-11-13
Director/Board Member 72 21-12-31
More insiders
NanoVibronix, Inc. is a medical device company. The Company is focused on developing noninvasive biological response-activating devices utilizing its low-intensity surface acoustic wave (SAW) technology. Its primary products consist of UroShield and PainShield. UroShield is an ultrasound-based product that is designed to prevent bacterial colonization and biofilm in urinary catheters, increase antibiotic efficacy and decrease pain and discomfort associated with urinary catheter use, which markets in the United States under Food and Drug Administration (FDA) policy of enforcement discretion during the COVID-19 pandemic and is undergoing clinical testing. PainShield is a patch-based therapeutic ultrasound technology to treat pain, muscle spasm and joint contractures by delivering a localized ultrasound effect to treat pain and induce soft tissue healing in a targeted area. Its PainShield family of products includes PainShield MD and PainShield Plus.
Calendar
More about the company